Michael E. Farkouh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael E. Farkouh has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Ashish Aneja
Division of Cardiovascular Medicine‐ Department of Medicine, Case Western Reserve University, Cleveland, OH
1 shared publicationBrandi E Robinson
1 shared publicationHeather J. Wiste
Division of Biomedical Statistics and Informatics‐ Department of Health Sciences Research, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN
1 shared publicationHuifeng Yun
1 shared publicationJames H. Chesebro
Division of Cardiology‐ Department of Medicine, University of Massachusetts Memorial Medical Center, Worcester, MA
1 shared publicationJoshua I. Mozes
Division of Cardiology‐ Department of Medicine, University of New Mexico, Albuquerque, NM
1 shared publication
Latest Publications
- 1 March 2016
- Vol. 22 (3) , e106-15
LDL cholesterol response and statin adherence among high-risk patients initiating treatment.
The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol treatment guideline recommends monitoring percent reduction in low-density lipoprotein cholesterol (LDL-C) among patients initiating statins as an indication of response and adherence. We examined LDL-C reduction and statin adherence among high-risk patients initiating statins in a real-world setting. Retrospective cohort study. The study population included Kaiser Permanente Georgia members (n = 1066) with a history of coronary heart disease or risk equivalent(s) initiating statins in 2011. Percent change in LDL-C was defined using measurements before and 60 to 450 days after statin initiation. Statin adherence was defined by proportion of days covered, categorized as high (≥80%), intermediate (50%-79%), and low (< 50%). Overall, 58.4% of patients failed to achieve a ≥ 30% LDL-C reduction after statin initiation. The prevalences of high, intermediate, and low statin adherence were 41.3%, 23.2%, and 35.6%, respectively. Of patients with high adherence, 42.3% did not achieve a ≥ 30% reduction in LDL-C compared with 54.7% and 79.7% of those with intermediate and low statin adherence, respectively. After multivariable adjustment, and compared with those with high adherence, the risk ratios for not achieving a ≥ 30% LDL-C reduction were 1.31 (95% CI, 1.13-1.52) and 1.88 (95% CI, 1.67-2.11), for those with intermediate and low adherence. Women and African Americans were less likely to have high adherence, whereas having cardiologist visits was associated with high adherence. In a real-world setting, many patients did not achieve a 30% or larger LDL-C reduction. These data support the ACC/AHA recommendation to monitor LDL-C response among patients initiating statins.
- 1 March 2016
- Vol. 22 (3) , e106-15
LDL cholesterol response and statin adherence among high-risk patients initiating treatment.
The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol treatment guideline recommends monitoring percent reduction in low-density lipoprotein cholesterol (LDL-C) among patients initiating statins as an indication of response and adherence. We examined LDL-C reduction and statin adherence among high-risk patients initiating statins in a real-world setting. Retrospective cohort study. The study population included Kaiser Permanente Georgia members (n = 1066) with a history of coronary heart disease or risk equivalent(s) initiating statins in 2011. Percent change in LDL-C was defined using measurements before and 60 to 450 days after statin initiation. Statin adherence was defined by proportion of days covered, categorized as high (≥80%), intermediate (50%-79%), and low (< 50%). Overall, 58.4% of patients failed to achieve a ≥ 30% LDL-C reduction after statin initiation. The prevalences of high, intermediate, and low statin adherence were 41.3%, 23.2%, and 35.6%, respectively. Of patients with high adherence, 42.3% did not achieve a ≥ 30% reduction in LDL-C compared with 54.7% and 79.7% of those with intermediate and low statin adherence, respectively. After multivariable adjustment, and compared with those with high adherence, the risk ratios for not achieving a ≥ 30% LDL-C reduction were 1.31 (95% CI, 1.13-1.52) and 1.88 (95% CI, 1.67-2.11), for those with intermediate and low adherence. Women and African Americans were less likely to have high adherence, whereas having cardiologist visits was associated with high adherence. In a real-world setting, many patients did not achieve a 30% or larger LDL-C reduction. These data support the ACC/AHA recommendation to monitor LDL-C response among patients initiating statins.
- 9 September 2010
- Published by Wiley in Clinical Cardiology
- Vol. 33 (9) , 553-558
Aspirin Use Is Associated With an Improved Long‐Term Survival in an Unselected Population Presenting With Unstable Angina
Background: Few published data are available on the benefits of aspirin use in patients with unstable angina (UA).Hypothesis: Aspirin use carries a mortality benefit in a population‐based cohort of patients presenting with UA.Methods: All residents of Olmsted County, Minnesota presenting to local emergency departments with acute chest pain from January 1985 through December 1992 having symptoms consistent with UA were identified through medical records. A total of 1628 patients were identified with UA and were stratified by aspirin use in‐hospital and at discharge. Cardiovascular mortality and nonfatal myocardial infarction and stroke were assessed over a median of 7.5 years follow‐up and all‐cause mortality data over a median of 16.7 years. The mean age of patients with UA was 65 years, and 60% were men.Results: After a median of 7.5 years follow‐up, all‐cause and cardiovascular‐mortality rates were lower among patients prescribed versus not prescribed aspirin on discharge. There were 949 postdischarge deaths over the median follow‐up of 16.7 years. After multivariable adjustment, aspirin use at discharge was associated with a lower long‐term mortality (hazard ratio 0.78; 95% confidence interval, 0.65–0.93).Conclusions: Aspirin use at hospital discharge following UA is associated with a reduction in long‐term mortality. This long‐term study extends prior trial results from select populations to a population‐based cohort. Copyright © 2010 Wiley Periodicals, Inc.This study was made possible by the Rochester Epidemiology Project (grant no. R01‐AR30582 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases). The authors have no other funding, financial relationships, or conflicts of interest to disclose.
- 9 September 2010
- Published by Wiley in Clinical Cardiology
- Vol. 33 (9) , 553-558
Aspirin Use Is Associated With an Improved Long‐Term Survival in an Unselected Population Presenting With Unstable Angina
Background: Few published data are available on the benefits of aspirin use in patients with unstable angina (UA).Hypothesis: Aspirin use carries a mortality benefit in a population‐based cohort of patients presenting with UA.Methods: All residents of Olmsted County, Minnesota presenting to local emergency departments with acute chest pain from January 1985 through December 1992 having symptoms consistent with UA were identified through medical records. A total of 1628 patients were identified with UA and were stratified by aspirin use in‐hospital and at discharge. Cardiovascular mortality and nonfatal myocardial infarction and stroke were assessed over a median of 7.5 years follow‐up and all‐cause mortality data over a median of 16.7 years. The mean age of patients with UA was 65 years, and 60% were men.Results: After a median of 7.5 years follow‐up, all‐cause and cardiovascular‐mortality rates were lower among patients prescribed versus not prescribed aspirin on discharge. There were 949 postdischarge deaths over the median follow‐up of 16.7 years. After multivariable adjustment, aspirin use at discharge was associated with a lower long‐term mortality (hazard ratio 0.78; 95% confidence interval, 0.65–0.93).Conclusions: Aspirin use at hospital discharge following UA is associated with a reduction in long‐term mortality. This long‐term study extends prior trial results from select populations to a population‐based cohort. Copyright © 2010 Wiley Periodicals, Inc.This study was made possible by the Rochester Epidemiology Project (grant no. R01‐AR30582 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases). The authors have no other funding, financial relationships, or conflicts of interest to disclose.